Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5195 ARTÍCULOS , VIENDO DEL 4681 AL 4695

Parkinson disease

Balestrino R, Schapira AHV.

Eur J Neurol. 2020 Jan;27(1):27-42. doi: 10.1111/ene.14108. Epub 2019 Nov 27.

Investigating Risk Factors and Predicting Complications in Deep Brain Stimulation Surgery with Machine Learning Algorithms

Farrokhi F, Buchlak QD, Sikora M, Esmaili N, Marsans M, McLeod P, Mark J, Cox E, Bennett C, Carlson J.

World Neurosurg. 2020 Feb;134:e325-e338. doi: 10.1016/j.wneu.2019.10.063. Epub 2019 Oct 18.

Association between REM sleep behavior disorder and impulsive-compulsive behaviors in Parkinson's disease: a systematic review and meta-analysis of observational studies

Lu HT, Shen QY, Zhao QZ, Huang HY, Ning PP, Wang H, Xie D, Xu YM.

J Neurol. 2020 Feb;267(2):331-340. doi: 10.1007/s00415-019-09588-3. Epub 2019 Oct 21.

Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia

Junior NCF, Dos-Santos-Pereira M, Guimarães FS, Del Bel E.

Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8. Epub 2019 Oct 22.

New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling

Naidoo D, Roy A, Slavětínská LP, Chukwujekwu JC, Gupta S, Van Staden J.

J Ethnopharmacol. 2020 Feb 10;248:112305. doi: 10.1016/j.jep.2019.112305. Epub 2019 Oct 19.

Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases

Heras-Sandoval D, Pérez-Rojas JM, Pedraza-Chaverri J.

Cell Signal. 2020 Jan;65:109442. doi: 10.1016/j.cellsig.2019.109442. Epub 2019 Oct 19.

Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease

Yonguc T, Sefik E, Inci I, Kusbeci OY, Celik S, Aydın ME, Polat S.

World J Urol. 2020 Aug;38(8):2013-2019. doi: 10.1007/s00345-019-02981-7. Epub 2019 Oct 23.

Are genetic and idiopathic forms of Parkinson's disease the same disease?

Correia Guedes L, Mestre T, Outeiro TF, Ferreira JJ.

J Neurochem. 2020 Mar;152(5):515-522. doi: 10.1111/jnc.14902. Epub 2019 Dec 8.

A phase 2, open-label, multi-center study to evaluate the efficacy and safety of (99m)Tc-TRODAT-1 SPECT to detect Parkinson's disease

Sun Y, Liu C, Chen Z, Li B, Lv Z, Lou J, Tang J, Wang Y, Zhang G, Liu X.

Ann Nucl Med. 2020 Jan;34(1):31-37. doi: 10.1007/s12149-019-01412-2. Epub 2019 Oct 23.

Biomarkers for Parkinson's Disease: How Good Are They?

Li T, Le W.

Neurosci Bull. 2020 Feb;36(2):183-194. doi: 10.1007/s12264-019-00433-1. Epub 2019 Oct 23.

Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: Pathogenic and therapeutic implications

Rani L, Mondal AC.

Mitochondrion. 2020 Jan;50:25-34. doi: 10.1016/j.mito.2019.09.010. Epub 2019 Oct 22.

Stem-Cell Research of Parkinson Disease: Bibliometric Analysis of Research Productivity from 1999 to 2018

Yang C, Wang X, Tang X, Wang R, Bao X.

World Neurosurg. 2020 Feb;134:e405-e411. doi: 10.1016/j.wneu.2019.10.087. Epub 2019 Oct 23.

Performance and Symptom Validity Assessment in Patients with Apathy and Cognitive Impairment

Dandachi-FitzGerald B, Duits AA, Leentjens AFG, Verhey FRJ, Ponds RWHM.

J Int Neuropsychol Soc. 2020 Mar;26(3):314-321. doi: 10.1017/S1355617719001139. Epub 2019 Oct 29.

Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

Coughlin DG, Hurtig HI, Irwin DJ.

Mov Disord. 2020 Jan;35(1):5-19. doi: 10.1002/mds.27867. Epub 2019 Oct 29.

Effect of simplified Tai Chi exercise on relieving symptoms of patients with mild to moderate Parkinson's disease

Zhu M, Zhang Y, Pan J, Fu C, Wang Y.

J Sports Med Phys Fitness. 2020 Feb;60(2):282-288. doi: 10.23736/S0022-4707.19.10104-1. Epub 2019 Oct 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias